Get the latest news, insights, and market updates on RLMD (Relmada Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
FDA written feedback supports: - a single-arm, open-label registrational trial in 2nd-line refractory high-grade NMIBC with CIS - a randomized vs observation single trial in intermediate-risk NMIBC in the adjuvant setting Phase 3 program expected to initiate in 1H 2026 CORAL GABLES, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous sy Jan 12, 2026 - $RLMD
Here Are Monday’s Top Wall Street Analyst Research Calls: BlackSky Technology, Cummins, Lamb Watson, Ollie’s Bargain Outlet, Sealed Air, Volaris, and More
Pre-Market Stock Futures: Futures are trading higher as we get ready to start a holiday-shortened trading week after an outstanding triple-witching Friday rally that may have kicked the “Santa Claus” rally into high gear. All of the major indices, including the Russell 2000, finished the day higher, and Oracle Corp. (NYSE: ORCL), which has been ... Here Are Monday’s Top Wall Street Analyst Research Calls: BlackSky Technology, Cummins, Lamb Watson, Ollie’s Bargain Outlet, Sealed Air, Volaris, and Dec 22, 2025 - $RLMD
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Relmada plans to advance NDV-01, a sustained release intravesical formulation of gemcitabine/docetaxel (Gem/Doce), into Phase 3 studies in two indications in H1 2026 Company is focused on high-risk NMIBC and intermediate-risk NMIBC, representing about 80% of new NMIBC cases every year, or about 54,000 people in the United States CORAL GABL Dec 3, 2025 - $RLMD
This Stock Is Up 704% in 2025 But Has No Products to Its Name
Relmada Therapeutics (RLMD) is a clinical-stage pharma company with no commercialized products and a $141 million market cap. RLMD has shown strong technical momentum, gaining 440% since August. Shares have a 100% “Buy” technical opinion from Barchart. Despite technical strength, RLMD lacks revenue, faces pipeline setbacks, and is rated “Hold”... Nov 20, 2025 - $RLMD
Relmada (RLMD) Q3 2025 Earnings Call Transcript
Need a quote from a Motley Fool analyst? With me on today's call are Relmada's CEO Dr. Sergio Traversa, who will briefly provide a summary of recent business highlights, Dr. Raj S. Pruthi, Relmada's CMO, who will provide an NDV-01 program update, and Relmada's CFO Maged S. Shenouda, who will provide an update on our financial results. Nov 13, 2025 - $RLMD
Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates
Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Secured FDA alignment on key elements of Phase 3 program with two independent paths for approval in two separate NMIBC indications: High-risk 2nd line BCG-unresponsive, and Intermediate-risk patients in the adjuvant setting; Studies expected to begin H1 2026 Completed $100M underwritten offering of common stock and pre-funded warra Nov 13, 2025 - $RLMD
Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025
CORAL GABLES, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2025 and recent business progress. Conference Call and Webcast Information: Nov 7, 2025 - $RLMD
Relmada Therapeutics Leads These 3 Promising Penny Stocks
On November 4, 2025, major U.S. stock indexes closed sharply lower, with tech stocks leading the decline and Bitcoin experiencing a notable drop. In such volatile market conditions, investors often seek out opportunities that might offer both affordability and growth potential. Penny stocks, though sometimes seen as relics of past market eras, continue to represent viable investment areas for those willing to explore smaller or newer companies with strong financial foundations. Nov 5, 2025 - $RLMD
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple